Objective: To provide an overview of onychomycosis and current treatments and to identify opportunities for pharmacy technicians to improve treatment outcomes. Data Sources: A MEDLINE/PubMed search (1966 to October 2018) was performed using search terms designed to identify English-language articles on onychomycosis diagnosis, treatment, and prevention, as well as articles on the impact of pharmacy technicians on onychomycosis outcomes and the use of pharmacy technicians to improve treatment adherence. Study Selection and Data Extraction: Review articles and clinical studies describing onychomycosis, risk factors, treatment efficacy, and prevention of recurrent infections were included. Data Synthesis: Although no articles on the impact of pharmacy technicians in the treatment of onychomycosis were found, the importance of treatment adherence on positive outcomes highlights a potential role of pharmacy technicians. Pharmacy technicians can identify patients with potential onychomycosis based on questions about over-the-counter products and refer patients to the pharmacist for counseling on treatment. Pharmacy technicians can also reinforce treatment adherence at refill visits. Conclusions: Pharmacy technicians can have a positive impact on onychomycosis treatment outcomes by addressing barriers to successful treatment and promoting treatment adherence.
ScherRKRichPPariserDElewskiB.The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;32(2suppl 1):S2-S4.
2.
GazesMIZeichnerJ.Onychomycosis in close quarter living review of the literature. Mycoses. 2013;56:610-613. doi:10.1111/myc.12088
3.
ElewskiBE.Onychomycosis. Treatment, quality of life, and economic issues. Am J Clin Dermatol. 2000;1:19-26.
4.
ShawJWJoishVNCoonsSJ.Onychomycosis: health-related quality of life considerations. Pharmacoeconomics. 2002;20:23-36.
5.
GuptaAKCerneaMFoleyKA.Improving cure rates in onychomycosis. J Cutan Med Surg. 2016;20:517-531.
6.
JinnaSFinchJ.Spotlight on tavaborole for the treatment of onychomycosis. Drug Des Devel Ther. 2015;9:6185-6190. doi:10.2147/DDDT.S81944
7.
TuckerRStewartD.An exploratory study of the views of community pharmacy staff on the management of patients with undiagnosed skin problems. Int J Pharm Pract. 2015;23:390-398. doi:10.1111/ijpp.12179
8.
ThomasJJacobsonGANarkowiczCKPetersonGMBurnetHSharpeC.Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35:497-519. doi:10.1111/j.1365-2710.2009.01107.x
9.
HayRJBaranR.Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol. 2011;65:1219-1227. doi:10.1016/j.jaad.2010.09.730
10.
FaergemannJBaranR.Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003;149(suppl 65):1-4.
11.
GuptaAKChangPDel RossoJQAdamPHofstaderSLR. Onychomycosis in children: prevalence and management. Pediatr Dermatol. 1998;15:464-471.
12.
MayserPFreundVBudihardjaD.Toenail onychomycosis in diabetic patients: issues and management. Am J Clin Dermatol. 2009;10:211-220. doi:10.2165/00128071-200910040-00001
13.
GuptaAKGuptaMASummerbellRCet al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol. 2000;14:466-469.
14.
GuptaAKTabordaPTabordaVet al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol. 2000;39:746-753.
15.
CrawfordFHollisSTopical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;(3):CD001434.
16.
BuckDSNidorfDMAddinoJG.Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. J Fam Pract. 1994;38:601-605.
17.
DerbyRRohalPJacksonCBeutlerAOlsenC.Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Fam Med. 2011;24:69-74. doi:10.3122/jabfm.2011.01.100124
18.
Romero-CereceroOZamilpaAJiménez-FerrerJERojas-BribiescaGRomán-RamosRTortorielloJ.Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. Planta Med. 2008;74:1430-1435.
GroverCKhuranaA.Onychomycosis: newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereol Leprol. 2012;78:263-270. doi:10.4103/0378-6323.95440
21.
BeckerCBershowA.Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. Dermatol Online J. 2013;19:19611.
22.
GuptaAKPaquetM.Management of onychomycosis in Canada in 2014. J Cutan Med Surg. 2015;19:260-273. doi:10.2310/7750.2014.14090
23.
GuptaAKVersteegSGShearNH.Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017;21:525-539. doi:10.1177/1203475417716362
24.
AmeenMLearJTMadanVMustapaMFMRichardsonM.British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171:937-958. doi:10.1111/bjd.13358
25.
TostiAHayRArenas-GuzmánR.Patients at risk of onychomycosis—risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005;19(suppl 1):13-16.
26.
LipnerSRScherRK. Part II: Onychomycosis: treatment and prevention of recurrence [published online June 27, 2018]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.05.1260
27.
MihalopoulosCCPowersMF.Roles for pharmacy technicians in community pharmacy practice accreditation. J Pharm Technol. 2013;29:111-117. doi:10.1177.875512251302900302
28.
MdegeNDChindoveS.Effectiveness of tobacco use cessation interventions delivered by pharmacy personnel: a systematic review. Res Social Adm Pharm. 2014;10:21-44. doi:10.1016/j.sapharm.2013.04.015
29.
SvarstadBLKotchenJMShiremanet al. Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial. J Am Pharm Assoc (2003). 2013;53:520-529. doi:10.1331/JAPhA.2013.12246
30.
AdhienPvan DijkLde VegterMWesteinMNijpelsGHugtenburgJG.Evaluation of a pilot study to influence medication adherence of patients with diabetes mellitus type-2 by the pharmacy. Int J Clin Pharm. 2013;35:1113-1119. doi:10.1007/s11096-013-9834-4
31.
RobinsonMGunningKPippittKMcAdam-MarxCJenningsBT.Team-based approach to addressing simvastatin safety concerns. J Am Pharm Assoc (2003). 2013;53:539-544. doi:10.1331/JAPhA.2013.13019
32.
EvansJLGladdEMGonzalezACet al. Establishing a clinical pharmacy technician at a United States Army military treatment facility. J Am Pharm Assoc (2003). 2016;56:573-579.e1. doi:10.1016/j.japh.2016.04.564
33.
KaaeSNørgaardLS.How to engage experienced medicine users at the counter for a pharmacy-based asthma inhaler service. Int J Pharm Pract. 2012;20:99-106. doi:10.1111/j.2042-7174.2011.00170.x
